Impact of Circulating Tumor DNA–Based Detection of Molecular Residual Disease on the Conduct and Design of Clinical Trials for Solid Tumors

Earlier detection of cancer recurrence using circulating tumor DNA (ctDNA) to detect molecular residual disease (MRD) has the potential to dramatically affect cancer management. We review evidence supporting the use of ctDNA as a biomarker for detection of MRD and highlight the potential impact that...

Descripción completa

Detalles Bibliográficos
Autores principales: Kasi, Pashtoon M., Fehringer, Gordon, Taniguchi, Hiroya, Starling, Naureen, Nakamura, Yoshiaki, Kotani, Daisuke, Powles, Thomas, Li, Bob T., Pusztai, Lajos, Aushev, Vasily N., Kalashnikova, Ekaterina, Sharma, Shruti, Malhotra, Meenakshi, Demko, Zachary P., Aleshin, Alexey, Rodriguez, Angel, Billings, Paul R., Grothey, Axel, Taieb, Julien, Cunningham, David, Yoshino, Takayuki, Kopetz, Scott
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer Health 2022
Materias:
Review Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926064/
https://www.ncbi.nlm.nih.gov/pubmed/35263168
http://dx.doi.org/10.1200/PO.21.00181

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8926064/
https://www.ncbi.nlm.nih.gov/pubmed/35263168
http://dx.doi.org/10.1200/PO.21.00181

Ejemplares similares